Chemical Component Summary

NameNICOTINIC ACID
Identifierspyridine-3-carboxylic acid
FormulaC6 H5 N O2
Molecular Weight123.109
TypeNON-POLYMER
Isomeric SMILESc1cc(cnc1)C(=O)O
InChIInChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
InChIKeyPVNIIMVLHYAWGP-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count14
Chiral Atom Count0
Bond Count14
Aromatic Bond Count6

Drug Info: DrugBank

DrugBank IDDB00627 
NameNiacin
Groups
  • investigational
  • approved
  • nutraceutical
DescriptionNiacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565]
Synonyms
  • pyridine-β-carboxylic acid
  • Niacina
  • β-pyridinecarboxylic acid
  • Acide nicotinique
  • Niacin
Brand Names
  • One Daily VITES
  • Vita-vim With Beta-carotene - Tab
  • Nata Komplete
  • Formula # 7 Tab 50mg
  • Gtf-vitamin-minerals & Pancreatin Tab
IndicationNiacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections.[L7550,L7553,L7556,L7559] Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia.[L7562,L7565] It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia.[L7562,L7565] Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia.[L7562,L7565] Finally niacin is indicated to treat severe hypertriglyceridemia.[L7562,L7565]
Categories
  • Agents Causing Muscle Toxicity
  • Cardiovascular Agents
  • Cytochrome P-450 CYP2D6 Inhibitors
  • Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)
  • Cytochrome P-450 CYP2E1 Inhibitors
ATC-Code
  • C10AD02
  • C10AD52
  • C10BA01
  • C04AC01
CAS number59-67-6

Drug Targets

NameTarget SequencePharmacological ActionActions
Hydroxycarboxylic acid receptor 3MNRHHLQDHFLEIDKKNCCVFRDDFIAKVLPPVLGLEFIFGLLGNGLALW...unknownagonist
Hydroxycarboxylic acid receptor 2MNRHHLQDHFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALW...unknownagonist
Nicotinate-nucleotide pyrophosphorylase [carboxylating]MDAEGLALLLPPVTLAALVDSWLREDCPGLNYAALVSGAGPSQAALWAKS...unknownbinder
Nicotinamide N-methyltransferaseMESGFTSKDTYLSHFNPRDYLEKYYKFGSRHSAESQILKHLLKNLFKIFC...unknownbinder
Cytochrome P450 2D6MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL573
PubChem 938, 117629482
ChEMBL CHEMBL573
ChEBI CHEBI:15940
CCDC/CSD AWUDEB, NICOAC01, GADQEL
COD 2311082, 2311084